Neoplasia Nomenclature, Hamartoma and Choristoma — Definitions, Comparisons and Exam Traps

The quickest way to distinguish these lesions is to ask what tissue is present, whether it belongs at that site, and how it is organised. A hamartoma contains tissue native to its location but in a disorganised arrangement. A choristoma contains normally formed tissue at an abnormal location. A teratoma is a germ-cell neoplasm capable of producing differentiated tissues from germ layers. Similar-looking tissue does not make the underlying lesions equivalent.

These terms describe different relationships between tissue and development. The word tumour can mean a mass without proving malignant behaviour. In a short pathology stem, “normal tissue” is therefore incomplete information: normal cellular appearance can coexist with abnormal architecture, an abnormal location, or a genuine germ-cell neoplasm. Read the anatomical site before deciding what the microscopic components mean.

A hamartoma is a local mass of disorganised tissue native to the anatomical site. The cells are generally cytologically bland, but their proportions or arrangement differ from normal tissue. This explains why the lesion can appear tumour-like without following the simple model of a malignant clone invading neighbouring structures. The classical teaching emphasises a developmental abnormality rather than assuming that every hamartoma is an ordinary autonomous neoplasm.

A pulmonary hamartoma can contain cartilage, fat and entrapped respiratory epithelium. The key is the abnormal assembly of components that are compatible with the local setting. In an image question, identify the components and then check the organ named in the stem. A mixture of mature tissues alone is insufficient to label a lesion as teratoma.

Most hamartomas are benign and may be discovered incidentally. Benign, however, does not mean clinically irrelevant: a lesion can obstruct a lumen, compress surrounding structures, bleed or produce symptoms because of its location. A hypothalamic lesion and a peripheral lung nodule demand different clinical reasoning even when both carry the word hamartoma.

A choristoma is a tumour-like mass of normally assembled tissue in the wrong anatomical location. “Normal” refers to its differentiation and architecture; “wrong” refers to the site. The tissue need not be cytologically atypical. The diagnosis therefore depends on the relationship between the microscopic findings and the clinical location, rather than on cellular appearance alone.

An osseous choristoma of the tongue provides a useful example: mature bone forms a discrete mass in lingual soft tissue. A chondroid choristoma similarly contains cartilage at an abnormal site. These examples are stronger than vague descriptions such as “bone somewhere outside a bone”, because tissue identity, mass formation and anatomical location are all specified.

Ectopia and heterotopia are related descriptions for tissue in an abnormal position. A choristoma usually emphasises the discrete mass formed by that tissue. Usage varies across organs and historical literature, so do not treat every occurrence of ectopic tissue as a new malignant tumour. Developmental displacement, altered differentiation and other mechanisms may be considered depending on the lesion.

A teratoma arises in the germ-cell tumour family and can contain tissues reflecting ectodermal, mesodermal and endodermal differentiation. Hair and skin suggest ectodermal differentiation; muscle, cartilage or bone suggest mesodermal differentiation; respiratory or gastrointestinal-type epithelium can represent endodermal differentiation. These tissue associations help interpret a specimen, but a single component is not enough to establish the entire diagnosis.

For ovarian lesions, separate mature cystic, immature, and monodermal teratomas. Mature cystic ovarian teratoma is also called a dermoid cyst and typically contains well-differentiated tissues. Immature teratoma contains immature elements and requires a different pathological assessment. Monodermal lesions have predominant specialised differentiation, with struma ovarii as a recognised example.

Mature cystic ovarian teratomas are generally benign, but malignant transformation can occur. Do not transfer the behaviour of an ovarian dermoid to every teratoma at every site. The pathological category, anatomical site and patient context matter. The aim of this comparison is recognition of the lesion family, not a universal rule that all mature-appearing germ-cell tumours behave identically.

Neoplastic nomenclature combines lineage or tissue of origin with information about differentiation or behaviour. A benign mesenchymal tumour often takes the tissue name followed by “oma”. A malignant mesenchymal tumour is usually named as a sarcoma. Malignant epithelial tumours are carcinomas. These conventions help organise a question, but historical names create important exceptions.

Use the name as a guide to tissue differentiation rather than proof of the exact normal cell that first acquired an alteration. An adenocarcinoma shows glandular differentiation; it need not arise in a structure colloquially called a gland. Similarly, a tumour displaying bone formation is classified by its pathological differentiation, which is more precise than guessing its identity from the organ alone.

The suffix does not replace examination of invasion, differentiation and the complete diagnostic label. A tumour can be malignant before metastasis is demonstrated. Conversely, a mass can be symptomatic without being malignant. For revision, keep nomenclature, biological behaviour and current clinical extent as related but separate questions.

The rule is a useful first pass, not a universal definition. Melanoma and lymphoma are classic malignant names ending in “oma”. These are common traps because the stem may ask about an exception rather than the usual naming convention. The full entity has an established meaning; removing the suffix and applying a mechanical rule loses that meaning.

Hamartoma and choristoma create a different trap. Their endings look like standard neoplasm names, yet the key concepts are abnormal assembly of local tissue and tissue misplaced into an abnormal site. Teratoma creates another: it names a germ-cell lesion rather than specifying a universal benign or malignant outcome. The examiner can test these distinctions without giving any laboratory results.

• Melanoma or lymphoma: recognise the established malignant entity despite the suffix.
• Hamartoma: interpret local components and abnormal organisation.
• Choristoma: interpret normal components and abnormal location.
• Teratoma: identify germ-cell differentiation, then determine the pathological category.

Pulmonary hamartoma links the definition to imaging: a sharply demarcated nodule may show popcorn calcification, and CT can demonstrate fat with calcific foci. These features support a diagnosis in the appropriate setting, but their absence does not automatically establish malignancy. The image is a clue to tissue composition, not a replacement for the clinical evaluation of a lung nodule.

Hypothalamic hamartoma connects a benign developmental lesion with serious site-related effects, including seizures or early pubertal manifestations. The lesson is that function and location can matter more than the word benign. A small lesion at a sensitive location may cause substantial morbidity without being a metastatic cancer.

Multiple hamartomas may occur within hereditary syndromes. PTEN hamartoma tumour syndrome, including the Cowden phenotype, is associated with increased cancer risk. This does not mean that every individual hamartoma is malignant. Distinguish a benign lesion, a syndrome that predisposes to malignancy, and a separate malignant tumour developing in that syndrome.

Mature cystic ovarian teratoma links differentiated tissues with a recognisable clinical lesion that can undergo torsion. Choristoma links ectopic tissue with local symptoms: even normal-looking tissue may need evaluation because the mass interferes with function or its diagnosis is uncertain. Management therefore follows location, symptoms and diagnostic confidence rather than a single vocabulary rule.

1. Identify the anatomical site before interpreting tissue components.
2. List the components: glandular epithelium, cartilage, bone, fat, skin or other differentiated tissues.
3. Ask whether these are native to the location and whether their arrangement is disorganised.
4. If normally formed tissue is ectopic and mass-forming, consider choristoma.
5. If the stem establishes germ-cell origin or a typical teratoma category, use the germ-cell classification.
6. Separately assess benignity, invasion and clinical consequences; do not derive them solely from the suffix.

For example, a circumscribed lung lesion containing disorganised cartilage and fat favours hamartoma. A lingual mass composed of mature bone favours osseous choristoma. An ovarian cyst containing hair and differentiated tissues favours mature cystic teratoma. These are illustrative revision vignettes, not a claim that a particular examination used those exact stems.